There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam CompoundersInvestors Business Daily • 07/23/26
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?Zacks Investment Research • 07/23/26
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 PoundsForbes • 07/23/26
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.The Motley Fool • 07/23/26
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trialsCNBC • 07/23/26
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CPRNewsWire • 07/23/26
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side24/7 Wall Street • 07/22/26
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters NowZacks Investment Research • 07/22/26
Lilly confirms date and conference call for second-quarter 2026 financial results announcementPRNewsWire • 07/22/26
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% laterReuters • 07/21/26
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.The Motley Fool • 07/21/26